These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 15827567)

  • 1. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
    Costemale-Lacoste JF; Guilloux JP; Gaillard R
    Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
    Gould TD; Picchini AM; Einat H; Manji HK
    Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
    Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
    J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
    Gould TD
    Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death.
    Jin N; Kovács AD; Sui Z; Dewhurst S; Maggirwar SB
    Neuropharmacology; 2005 Mar; 48(4):576-83. PubMed ID: 15755485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Wnt signaling pathway in bipolar disorder.
    Gould TD; Manji HK
    Neuroscientist; 2002 Oct; 8(5):497-511. PubMed ID: 12374432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of glycogen synthase kinase-3beta in schizophrenia.
    Koros E; Dorner-Ciossek C
    Drug News Perspect; 2007 Sep; 20(7):437-45. PubMed ID: 17992266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.
    Einat H; Manji HK
    Biol Psychiatry; 2006 Jun; 59(12):1160-71. PubMed ID: 16457783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge.
    Ikonomov OC; Manji HK
    Am J Psychiatry; 1999 Oct; 156(10):1506-14. PubMed ID: 10518159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
    Cole AR
    FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of protein L-isoaspartyl methyltransferase expression by lithium is mediated by glycogen synthase kinase-3 inactivation and beta-catenin stabilization.
    Lamarre M; Desrosiers RR
    Neuropharmacology; 2008 Oct; 55(5):669-76. PubMed ID: 18582478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors.
    Gould TD; Einat H; O'Donnell KC; Picchini AM; Schloesser RJ; Manji HK
    Neuropsychopharmacology; 2007 Oct; 32(10):2173-83. PubMed ID: 17299510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
    Sutton LP; Rushlow WJ
    Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
    Wada A
    J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.
    Leng Y; Liang MH; Ren M; Marinova Z; Leeds P; Chuang DM
    J Neurosci; 2008 Mar; 28(10):2576-88. PubMed ID: 18322101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
    Gould TD; Zarate CA; Manji HK
    J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks.
    Padiath QS; Paranjpe D; Jain S; Sharma VK
    Chronobiol Int; 2004 Jan; 21(1):43-55. PubMed ID: 15129823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.